SEHK:1177Pharmaceuticals
Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After New GSK Partnership On Hepatitis B Drug Candidate
Sino Biopharmaceutical (SEHK:1177) has drawn fresh investor attention after subsidiary Chia Tai Tianqing agreed an exclusive partnership with GSK to commercialise bepirovirsen for chronic hepatitis B in mainland China.
See our latest analysis for Sino Biopharmaceutical.
The partnership news lands after a mixed price run, with the stock up 2.12% on a 1 day share price return and 6.25% over 7 days, yet down 15.37% over 90 days. The 1 year total shareholder return of 52.60% contrasts with weaker...